A Phase 3, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in participants with isocitrate dehydrogenase 1 (IDH1)-mutant glioma

Contact:

212-342-5162

NCT Number:

NCT05303519

Protocol:

AAAU6265

Study Status:

Active/Enrolling

Population:

Adult

Phase:

II

The purpose of this study is to see how safe and effective Safusidenib erbumine, the study drug, is in treating brain glioma and to find the recommended dose of the study drug for clinical studies. Safusidenib is not Food and Drug Administration (FDA) approved.

Are you Eligible? (Inclusion Criteria)

  • Must be 18 years old or older - Must have have life expectancy 3 months or more - Must have negative result for COVID

Specialty Area(s)

Brain and Spinal Tumors, Immunotherapy

Principal Investigator

Andrew B. Lassman, MD, FAAN, FASCO

Profile Headshot
  • Vice Chair of Clinical Research, Department of Neurology
  • Chief, Division of Neuro-Oncology
  • Associate Dean of Clinical Research Compliance, Vagelos College of Physicians & Surgeons
  • Associate Director for Clinical Trials, Herbert Irving Comprehensive Cancer Center
  • Scientific Director, Network Capacity Resource, Irving Institute for Clinical & Translational Research

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Open location CUIMC/Herbert Irving Pavilion in Google Maps
Back to top